Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
The present invention discloses compounds according to Formula I: Wherein R 1a , R 1b , R 2 , R 4 , R 5 , R 6a , R 6b , R 8 , W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
1. A compound of the formula:
or a pharmaceutically acceptable salt, or a solvate, or a pharmaceutically acceptable salt of a solvate thereof.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 .
4. A pharmaceutical composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt, or a solvate, or a pharmaceutically acceptable salt of a solvate thereof, and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4 , comprising a further therapeutic agent.
6. The pharmaceutical composition according to claim 5 , wherein the further therapeutic agent is an agent for the treatment of idiopathic pulmonary fibrosis.
7. The pharmaceutical composition according to claim 4 , comprising the compound of the formula:
or a pharmaceutically acceptable salt thereof.
8. The pharmaceutical composition according to claim 7 , comprising a further therapeutic agent.
9. The pharmaceutical composition according to claim 8 , wherein the further therapeutic agent is for the treatment of idiopathic pulmonary fibrosis.
10. The pharmaceutical composition according to claim 4 comprising the compound of the formula:
11. The pharmaceutical composition according to claim 10 , comprising a further therapeutic agent.
12. The pharmaceutical composition according to claim 11 , wherein the further therapeutic agent is for the treatment of idiopathic pulmonary fibrosis.
13. A method of inhibiting ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), which method comprises contacting the ENPP2 with a compound according to claim 1 , or a pharmaceutically acceptable salt, or a solvate, or a pharmaceutically acceptable salt of a solvate thereof.
14. The method of inhibiting ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) according to claim 13 , which method comprises contacting the ENPP2 with the compound of the formula:
or a pharmaceutically acceptable salt thereof.
15. The method of inhibiting ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) according to claim 13 , which method comprises contacting the ENPP2 with the compound of the formula: